Sentinel Lymph Node Mapping Post-Injection Site Pain
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This is a pain survey study that will compare the level of discomfort experienced by breast
cancer patients after injection of either technetium-labeled sulfur colloid or
technetium-labeled tilmanocept, both FDA-approved agents used for sentinel lymph node biopsy
(SLNB). Breast cancer patients who are already scheduled for SLNB as part of their original
surgical plan will be asked to participate in this study and be randomized to receive either
technetium-labeled sulfur colloid or technetium-labeled tilmanocept. After injection,
patients will complete pain questionnaires to measure the amount of discomfort they are
feeling during and after they receive the injection. There will be no change to the patient's
treatment plan other than the addition of pain questionnaires. The investigators' hypothesis
is that patients will feel less discomfort after injection of tilmanocept versus sulfur
colloid.